Key Takeaways
- Standard Dosage Range: Vilon is typically administered in the range of 5-10 mg per week, depending on the form and therapeutic goal.
- Administration Method: Primarily administered subcutaneously or intramuscularly; oral forms are less common due to lower bioavailability.
- Typical Cycle Length: Treatment cycles generally last 4-6 weeks, with adjustments based on clinical response.
- Regulatory Status: Vilon is not FDA-approved and is available for research purposes only.
- Medical Supervision: Always consult a healthcare provider before starting Vilon therapy to ensure safe and effective use.
How Vilon Works in the Body
Vilon, a short peptide bioregulator, plays a significant role in modulating gene expression and chromatin structure. The peptide's mechanism of action involves the reactivation of chromatin and the regulation of protein synthesis, which influences cell cycle homeostasis. The pharmacokinetics of Vilon, including receptor binding and bioavailability, are crucial in determining appropriate dosing regimens.
Vilon's receptor binding affinity contributes to its ability to modulate chromatin structure, as evidenced by studies on lymphocytes from elderly individuals. These studies, such as the one published in Biogerontology (PMID 15105581), demonstrated that Vilon induces deheterochromatinization, which leads to the activation of ribosomal genes. The half-life of Vilon, while not extensively documented, is estimated to be short, necessitating frequent administration to maintain therapeutic levels.
"The effect of synthetic peptide bioregulators (Epitalon, Livagen, and Vilon) on structural and facultative heterochromatin of cultivated lymphocytes have been studied among old (75-88yr.) people. The data obtained indicate that Vilon: 1) activates synthetic processes, caused by reactivation of ribosomal genes as a result of deheterochromatinization (decondensation) of nucleolus organizer regions; 2) induces unrolling (deheterochromatinization) of total heterochromatin." (PMID 16705247)
Standard Vilon Dosage Ranges (By Form)
Subcutaneous Administration
- Dosage Range: 5-10 mg per week, divided into daily or every-other-day injections.
- Frequency: Typically administered 2-3 times per week.
- Bioavailability: Subcutaneous administration provides moderate bioavailability, making it a preferred method for consistent plasma levels.
Intramuscular Administration
- Dosage Range: Similar to subcutaneous, 5-10 mg per week.
- Frequency: Usually administered once or twice a week.
- Bioavailability: Slightly higher than subcutaneous due to deeper tissue penetration.
Oral Administration
- Dosage Range: Higher doses may be required, typically 10-20 mg per day, due to reduced bioavailability.
- Frequency: Daily administration is common.
- Bioavailability: Significantly lower, as oral peptides often face degradation in the gastrointestinal tract.
Vilon Dosage by Use Case
Gene Expression Modulation
- Typical Dosage Range: 5-10 mg per week.
- Administration Method: Subcutaneous or intramuscular.
- Cycle Length: 4-6 weeks.
- Clinical Reference: Studies suggest Vilon's role in chromatin reactivation, enhancing gene expression (PMID 15105581).
Chronic Renal Failure
- Typical Dosage Range: 5 mg per week.
- Administration Method: Subcutaneous.
- Cycle Length: 2-4 months.
- Clinical Reference: Research indicates Vilon decreases serum TGF-beta and improves microvessel permeability (PMID 16142267).
Anti-Carcinogenic Effects
- Typical Dosage Range: 5-10 mg per week.
- Administration Method: Subcutaneous.
- Cycle Length: 6-12 weeks.
- Clinical Reference: Vilon has been shown to reduce the incidence of preneoplastic changes in rat models (PMID 11586406).
How Long Should You Take Vilon?
Typical Vilon treatment cycles last between 4 to 6 weeks, with some protocols extending up to 12 weeks depending on therapeutic goals and patient response. Initial effects may be observed within the first 2-4 weeks, but full benefits often require completion of the entire cycle. Tapering is generally not necessary, but discontinuation should be supervised by a healthcare provider. Studies on long-term use are limited, and ongoing monitoring for adverse effects is recommended.
Administration Protocol: How to Inject Vilon
Injection Technique
- Needle Gauge: 29-31 gauge, 1/2 inch insulin syringe.
- Injection Depth: Subcutaneous injections should be shallow, approximately 45-degree angle.
- Injection Sites: Rotate between the abdomen (2 inches from the navel), thigh, and upper arm to minimize tissue irritation.
Timing and Storage
- Timing: Administer injections in the morning or evening, depending on patient preference. Avoid injecting immediately before or after meals.
- Storage Requirements: Store lyophilized Vilon at 36-46°F (2-8°C). Reconstituted solutions should be used within 14 days and protected from light.
Reconstitution Instructions
- Follow our reconstitution guide for detailed steps on preparing Vilon for injection.
Step-by-Step Administration Process
- Wash hands thoroughly and prepare the injection site with an alcohol swab.
- Draw the prescribed dose into the syringe, ensuring no air bubbles remain.
- Pinch the skin at the injection site and insert the needle at a 45-degree angle.
- Inject the solution slowly and steadily.
- Withdraw the needle and apply gentle pressure with a clean swab.
Stacking Vilon for Better Results
Vilon and Epitalon
- Combination: Often combined with Epitalon for synergistic effects on chromatin structure.
- Dosing Synergy: Vilon 5 mg/week with Epitalon 10 mg/week.
- Protocol: Known as part of the "Wolverine protocol," enhancing anti-aging effects.
Vilon and Thymosin Beta-4
- Combination: Used with Thymosin Beta-4 for tissue repair.
- Dosing Synergy: Vilon 5 mg/week with Thymosin Beta-4 2 mg/week.
- Protocol: Common in regenerative medicine protocols.
Factors That Affect Your Vilon Dosage
Several factors can influence the appropriate dosing of Vilon, including body weight, age, specific treatment goals, and individual response to therapy. Patients with compromised kidney or liver function may require dose adjustments. A healthcare provider will consider these factors to tailor the dosage to each patient's needs, emphasizing that a one-size-fits-all approach is ineffective.
